Literature DB >> 27074870

Challenges in establishing the diagnosis of human papillomavirus-related oropharyngeal carcinoma.

Michelle Truong Lam1, Brian O'Sullivan2,3, Patrick Gullane3, Shao Hui Huang4,5.   

Abstract

OBJECTIVES/HYPOTHESIS: To describe initial presentations and idiosyncrasies in establishing the diagnosis for human papillomavirus-related (HPV(+) ) compared to HPV-unrelated (HPV(-) ) oropharyngeal carcinoma (OPC). STUDY
DESIGN: A single institution retrospective series derived from an institutional prospectively compiled database supplemented by chart review.
METHODS: We reviewed consecutive OPC patients referred to an academic tertiary cancer center from 2009 to 2011. HPV status was evaluated by p16 staining. Signs/symptoms and procedures to establish diagnosis were recorded independently by two abstractors blinded to the HPV status during data retrieval. Initial presentations (signs/symptoms), interval, and the procedures to establish the diagnosis were compared between HPV(+) and HPV(-) OPC.
RESULTS: The most common initial presentation was an asymptomatic nodal mass for HPV(+) patients (n = 208; 69% vs. 29%, P < .001) in contrast to dysphagia/odynophagia for HPV(-) (n = 96; 34% vs. 63%, P < .001). Protracted interval (>12 months) from onset of signs/symptoms to diagnosis was observed in 18 (9%) HPV(+) versus three (3%) HPV(-) patients (P = .058). More HPV(+) patients required repeated (≥2) biopsy procedures (56% vs. 10%, P < .001). Misattribution to other disease occurred in eight (4%) HPV(+) patients (seven were mistaken as having a "branchial cleft cyst" when there were cystic lymph nodes and one as having a "lymphoma") compared to none in HPV(-) .
CONCLUSIONS: About two-thirds of HPV(+) patients present with an asymptomatic neck mass and often require multiple biopsy procedures to establish the diagnosis. Idiosyncrasies in appreciating the diagnostic setting (cystic lymph node, misattribution to other entities, or submucosal location of the tumor) or patient-related factors could delay the diagnosis of HPV(+) OPC. LEVEL OF EVIDENCE: 4 Laryngoscope, 126:2270-2275, 2016.
© 2016 The American Laryngological, Rhinological and Otological Society, Inc.

Entities:  

Keywords:  Oropharyngeal carcinoma; clinical presentation; diagnosis; human papillomavirus

Mesh:

Year:  2016        PMID: 27074870     DOI: 10.1002/lary.25985

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  5 in total

Review 1.  Data Set for the Reporting of Carcinomas of the Nasopharynx and Oropharynx: Explanations and Recommendations of the Guidelines From the International Collaboration on Cancer Reporting.

Authors:  James S Lewis; David J Adelstein; Abbas Agaimy; Diane L Carlson; William C Faquin; Tim Helliwell; Jos Hille; Tony Ng; John M Nicholls; Brian O'Sullivan; Lester D R Thompson
Journal:  Arch Pathol Lab Med       Date:  2018-11-30       Impact factor: 5.534

2.  Human papillomavirus in oropharyngeal cancer in Canada: analysis of 5 comprehensive cancer centres using multiple imputation.

Authors:  Steven Habbous; Karen P Chu; Harold Lau; Melissa Schorr; Mathieos Belayneh; Michael N Ha; Scott Murray; Brian O'Sullivan; Shao Hui Huang; Stephanie Snow; Matthew Parliament; Desiree Hao; Winson Y Cheung; Wei Xu; Geoffrey Liu
Journal:  CMAJ       Date:  2017-08-14       Impact factor: 8.262

3.  From presumed benign neck masses to delayed recognition of human papillomavirus-positive oropharyngeal cancer.

Authors:  Ruth J Davis; Eleni Rettig; Nafi Aygun; Lisa Rooper; Gypsyamber D'Souza; David W Eisele; Carole Fakhry
Journal:  Laryngoscope       Date:  2019-04-05       Impact factor: 3.325

4.  Factors influencing patient and health care delays in Oropharyngeal Cancer.

Authors:  Markus Nieminen; Timo Atula; Leif Bäck; Antti Mäkitie; Lauri Jouhi; Katri Aro
Journal:  J Otolaryngol Head Neck Surg       Date:  2020-04-23

Review 5.  Therapeutic options for treatment of human papillomavirus-associated cancers - novel immunologic vaccines: ADXS11-001.

Authors:  Brett Miles; Howard P Safran; Bradley J Monk
Journal:  Gynecol Oncol Res Pract       Date:  2017-07-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.